Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

What it does

This proposed rule would codify the Medicare Drug Price Negotiation Program ("Negotiation Program") and would establish certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. This proposed rule would also propose a modification to the fixed combination drug policy.

The Centers for Medicare & Medicaid Services's summary, as published in the Federal Register.

What it would change

2 parts of Title 42 of the Code of Federal Regulations:

42 CFR 423, 42 CFR 429

Before this

No earlier Federal Register document under regulation identifier 0938-AV90 since Jan. 1, 2025.

Since then:

• Nov. 9, 2026 Final rule. Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

What happens next and when

To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on August 17, 2026.

The agency's dates, word for word.

Check it yourself

• The document in the Federal Register
• Docket CMS-2026-2080 on Regulations.gov
• Title 42 on eCFR

The record as published

Source: the Federal Register (public domain). The document in the Federal Register